text: In addition, << sorafenib >> demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including [[ vascular-endothelial growth factor (VEGFR)-2 ]], VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT.